--- title: "ETHK Labs Warns of Sharp 2025 Profit Drop Amid Margin Squeeze and Listing Costs" type: "News" locale: "en" url: "https://longbridge.com/en/news/278749773.md" description: "ETHK Labs Inc., a Hong Kong-listed in vitro diagnostics company, has warned of a significant profit drop for 2025, projecting earnings to fall to approximately RMB42.2 million from RMB260.4 million the previous year. The decline is attributed to increased competition, higher administrative costs related to U.S. listing preparations, and rising finance costs. The company is also pursuing a dual listing in the U.S. to enhance financing options. The latest analyst rating for its stock (HK:1931) is a Hold with a price target of HK$1.50." datetime: "2026-03-11T15:09:57.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/278749773.md) - [en](https://longbridge.com/en/news/278749773.md) - [zh-HK](https://longbridge.com/zh-HK/news/278749773.md) --- # ETHK Labs Warns of Sharp 2025 Profit Drop Amid Margin Squeeze and Listing Costs ### Claim 70% Off TipRanks Premium - Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions - Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential IVD Medical Holding Limited ( (HK:1931) ) has shared an update. ETHK Labs Inc., a Hong Kong-listed in vitro diagnostics company incorporated in the Cayman Islands, develops and sells IVD products in an increasingly competitive market. The Group is also working toward a proposed dual listing in the United States to broaden its financing channels and back ongoing expansion. The company has warned that profit attributable to shareholders for 2025 is expected to fall sharply to no more than about RMB42.2 million from RMB260.4 million a year earlier. Management attributes the decline to margin pressure from tougher IVD competition, higher administrative expenses tied to U.S. listing preparations, and increased finance costs from greater borrowings, and has cautioned investors as the figures remain unaudited and subject to adjustment. The most recent analyst rating on (HK:1931) stock is a Hold with a HK$1.50 price target. To see the full list of analyst forecasts on IVD Medical Holding Limited stock, see the HK:1931 Stock Forecast page. **More about IVD Medical Holding Limited** ETHK Labs Inc., incorporated in the Cayman Islands and listed in Hong Kong, operates in the in vitro diagnostics (IVD) industry. The Group focuses on IVD products and services in a competitive operating environment, and is pursuing a proposed dual listing in the United States to support its business expansion and capital needs. **Average Trading Volume:** 4,698,216 **Technical Sentiment Signal:** Sell **Current Market Cap:** HK$1.95B For a thorough assessment of 1931 stock, go to TipRanks’ Stock Analysis page. ### Related Stocks - [01931.HK](https://longbridge.com/en/quote/01931.HK.md) ## Related News & Research - [ETHK Labs Rebrands with New English Name and Stock Short Name in Hong Kong](https://longbridge.com/en/news/273715634.md) - [11:05 ETThe Church of Jesus Christ of Latter-day Saints Commits $25 Million to the UNICEF-led Child Nutrition Fund](https://longbridge.com/en/news/287088476.md) - [Mabwell Wins Wider China Indications for Denosumab Biosimilar as Global Push Accelerates](https://longbridge.com/en/news/287103520.md) - [13:41 ETUT Haslam Marks Decade in Major International Ranking's Top Five U.S. Public Schools](https://longbridge.com/en/news/286804132.md) - [Dunkin' To Give Away 1 Mln Free Coffees For A Day](https://longbridge.com/en/news/286964019.md)